Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.43 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.43 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.43 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28999643 | 0.85 | CSNK2A1 (0.50) | BACE1CSNK2A1CYP2A6PRKAB2PRKAG1 | |
| SCHEMBL28942599 | 0.84 | CNR1 (0.47) | BACE1CSNK2A1CYP2A6MAOBHTR1A | |
| SCHEMBL27746382 | 0.84 | TDP1 (0.47) | BACE1TDP1CSNK2A1CYP2A6MAOB | |
| SCHEMBL15679162 | 0.79 | CSNK2A1 (0.49) | CSNK2A1CYP2A6MAOBHTR1AHTR7 | |
| SCHEMBL2779989 | 0.79 | CSNK2A1 (0.49) | BACE1CSNK2A1CYP2A6MAOBHTR1A | |
| SCHEMBL15224151 | 0.79 | BACE1 (0.74) | BACE1TDP1KDM4EALDH1A1ALOX5 | |
| SCHEMBL2780701 | 0.79 | CSNK2A1 (0.73) | BACE1CSNK2A1CYP2A6MAOBFFAR1 | |
| SCHEMBL27509606 | 0.78 | BACE1 (0.53) | BACE1TDP1CSNK2A1MAOBKDM4E | |
| Hydrochloric Acid SCHEMBL2780404 | 0.78 | CSNK2A1 (0.74) | BACE1CSNK2A1CYP2A6MAOBFFAR1 | |
| SCHEMBL28408910 | 0.77 | CCR1 (0.40) | HTR1AKDM4EALDH1A1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110225911-B | Oxadiazolone transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3544979-B1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| EP-3544979-B1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3544979-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-10-02 | — | — | EP | disclosed |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | BACE1 1844/4885TDP1 2596/4885CSNK2A1 1714/4885 |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | BACE1 1844/4885TDP1 2596/4885CSNK2A1 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.